S 3304

Research use only, not for human use.

S 3304 is a novel matrix metalloproteinases inhibitor which is specific for MMP-2 and MMP-9.

S 3304 is a novel matrix metalloproteinases inhibitor which is specific for MMP-2 and MMP-9. (In Vitro):S 3304 is a novel D-tryptophan derivative and a potent, orally active, noncytotoxic Matrix metalloproteinases inhibitor (MMPI). Biochemical studies show that S 3304 most potently inhibits the activities of MMP-2 and MMP-9 but does not inhibit MMP-1, MMP-3, or MMP-7 and may, therefore, lack the musculoskeletal side effects seen with nonspecific inhibitors.(In Vivo):In vivo pharmacologic studies have shown that the oral administration of S 3304, at a dose range of 20 to 200 mg/kg, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 result in potent inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen.

S 3304 is a novel D-tryptophan derivative and a potent, orally active, noncytotoxic Matrix metalloproteinases inhibitor (MMPI). Biochemical studies show that S 3304 most potently inhibits the activities of MMP-2 and MMP-9 but does not inhibit MMP-1, MMP-3, or MMP-7 and may, therefore, lack the musculoskeletal side effects seen with nonspecific inhibitors.

In vivo pharmacologic studies have shown that the oral administration of S 3304, at a dose range of 20 to 200 mg/kg, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 result in potent inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen.

——

Metabolic Enzyme/Protease

MMP

MMP-2|MMP-9

——

——

203640-27-1

464.56

C24H20N2O4S2

>98% (HPLC)

DMSO:83.3 mg/mL (179.31 mM)

Cc(cc1)ccc1C#Cc(s1)ccc1S(N[C@H](Cc1c[nH]c2c1cccc2)C(O)=O)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years